PDCD1 and neoplasm: Aldometanib did not affect the numbers of stem-like CD8+ T cells (PD-1+CD44+Tim3−Tcf7+) or terminally exhausted CD8+ T cells (CD8+ Tex; PD-1+CD44+Tim3+Tcf7−) (Supplementary information, Fig. S8n), indicative of the presence of long-lasting anti-tumor immunity and an effective immune surveillance mechanism.